"Those who share the same aspirations do not consider mountains and seas as distances." On the afternoon of February 2,HTA"Join Hands for a Shared Future, Cooperate for a New Chapter": GE Healthcare and HTA Co., Ltd. Host Signing Ceremony in Beijing. Gathering Strength, Innovating Collaboration, and Signing Agreements on Cooperation in the Field of Nuclear Medicine Diagnostic Drugs to Jointly Promote High-Quality Development of the Global Nuclear Medicine Industry.

Zhang Junqi, Party Secretary of China Isotope & Radiation, Zhang Yihao, Global Executive Vice President of GE Healthcare, President and CEO of GE Healthcare China, and Nguyen, Quang Trung, Global Director of Nuclear Medicine Products at GE Healthcare, attended and witnessed the signing ceremony. Kevin O’Neill, Global Vice President of GE Healthcare and Global CEO of Diagnostic Drugs, and Casey Julia, Global General Manager of Nuclear Medicine at GE Healthcare Diagnostic Drugs, delivered video speeches. Zhao Jing, General Manager of HTA Co., Ltd., and Xiao Yindi, Vice President of GE Healthcare China and General Manager of Diagnostic Drugs Business, signed the cooperation agreement on behalf of both parties.

Zhang Yihao stated that this cooperation between the two parties is the best practice for Chinese enterprises and international companies to strengthen collaboration, using healthcare as a bridge to promote a common destiny for humanity. It is another significant milestone in GE Healthcare's China strategy of "comprehensive localization, limitless innovation, and win-win cooperation." Defeating diseases requires innovation, and under the joint efforts of both parties, this innovative collaboration will accelerate the clinical application of new drugs in the neurology field.Nuclear Medicine TechnologyCollaborate to overcome the early diagnosis and treatment of serious diseases, benefit patients, explore a modernized path for universal health in China, promote the accessibility of precision medicine and high-quality medical resources, and create boundless medical care to cherish every important moment in the lives of the Chinese people.

Yindi Xiao stated that the cooperation between GE Healthcare and HTA Co., Ltd. is a significant milestone, marking an important step in the localization of GE Healthcare's high-end nuclear medicine in China. With a shared vision, both parties are exploring mutually beneficial cooperation, jointly promoting the localization of international high-end nuclear medicine in China, and contributing to the realization of the "Healthy China 2030" strategy.

Zhang Junqi stated that this cooperation marks the first collaboration between China Isotope & Radiation Corporation (CIRC), HTA, and GE Healthcare in the field of nuclear medicine. It also represents a further deepening of the comprehensive partnership between CIRC and GE Healthcare. This collaboration holds significant importance for promoting the innovative and high-quality development of China-produced advanced nuclear medicines and nuclear medical imaging equipment on a global scale. Given the increasing demand for nuclear medicine in China, HTA and GE Healthcare have highly aligned industrial development goals and business strategies. The in-depth strategic partnership reached in this collaboration will help innovate the cooperation model between state-owned enterprises and leading international pharmaceutical equipment companies, supporting the advancement of a new generation of technologies domestically.RadiopharmaceuticalsThe rapid development.

As a leading enterprise in China that integrates research and development, production, sales, and services in the field of nuclear technology applications, HTA Co., Ltd. will take this cooperation as a starting point to actively respond to the Group's initiative of "Synergy with Me, Advancing CNNC." With a holistic approach, the company will strengthen industrial synergy, deepen the upstream and downstream collaborative chain of the nuclear technology application industry, fully leverage the advantages of powerful alliances, innovate cooperation models, integrate high-quality resources, and collaborate with GE Healthcare to focus on early detection of serious diseases and integrated diagnosis and treatment through precision medical technology innovation. Together, they will map out the development blueprint for domestically produced high-end nuclear medicine and nuclear medicine imaging equipment, benefiting global public health.

Chief Talent Officer of GE Healthcare China, GE Healthcare China Financial Services andTreasuryAnd the business development leader, Manager of the Nuclear Medicine Products Department of GE Healthcare China Diagnostic Pharmaceuticals Business, as well as relevant leaders and departments from HTA and CNNC High Energy participated in the signing event.